SK Biopharmaceuticals Co., Ltd. (326030.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	861.3B	706.7B	547.6B	354.9B	246.2B
Cost of Revenue	69.8B	55.1B	43.1B	34.1B	37.8B
Gross Profit	791.5B	651.7B	504.5B	320.8B	208.4B
Operating Expenses
R&D Expense	140.4B	174.3B	161.3B	137.7B	122.8B
SG&A Expense	203.1B	146.3B	114.8B	204.3B	112.3B
General & Admin Expense	87.4B	80.6B	63.9B	61.7B	62.4B
Selling & Marketing Expense	74.1B	65.7B	50.9B	40.1B	49.9B
Other Expenses	206.1B	127.1B	132.1B	16.3B	104.4B
Total Operating Expenses	497.7B	447.7B	408.2B	358.3B	339.5B
Cost and Expenses	558.1B	502.8B	451.3B	393.0B	377.3B
Operating Income (EBIT)	303.2B	203.9B	96.3B	(20.6B)	(131.1B)
Non-Operating
Interest Income	7.7B	7.1B	10.1B	9.3B	6.8B
Interest Expense	5.6B	7.7B	10.7B	8.3B	3.7B
Net Interest Income	2.1B	(606.1M)	(536.3M)	1.0B	3.0B
Other Non-Op Income/Expense	(14.0B)	(53.1B)	(23.7B)	(23.2B)	(11.4B)
Non-Operating Income (excl Interest)	17.5B	—	13.1B	(1.9B)	7.7B
EBT (Pre-Tax Income)	289.2B	150.9B	72.6B	(43.9B)	(142.5B)
Income Tax Expense	(102.7B)	(102.4B)	(154.4B)	(8.5B)	(3.0B)
Bottom Line
Net Income	401.0B	267.0B	240.7B	(32.9B)	(139.4B)
Earnings from Cont. Ops	391.9B	253.3B	227.0B	(35.4B)	(139.4B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	401.0B	267.0B	240.7B	(32.9B)	(139.4B)
Per Share
Basic EPS	₩4,945	₩3,409	₩3,067	(₩420)	(₩1,780)
Diluted EPS	₩4,945	₩3,409	₩3,067	(₩420)	(₩1,780)
Revenue Per Share	₩10,999	₩9,025	₩6,992	₩4,532	₩3,144
Shares
Basic Shares Outstanding	78.3M	78.3M	78.3M	78.3M	78.3M
Diluted Shares Outstanding	78.3M	78.3M	78.3M	78.3M	78.3M
Profitability Metrics
EBITDA	236.0B	220.9B	100.7B	(8.7B)	(125.8B)
D&A	15.9B	16.9B	17.4B	15.3B	13.0B
EBIT	220.1B	203.9B	83.3B	(24.0B)	(138.8B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026